Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-ZrGlobeNewsWire • 09/12/24
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced CancersGlobeNewsWire • 08/21/24
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-ZrGlobeNewsWire • 08/14/24
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent DevelopmentsGlobeNewsWire • 08/09/24
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24GlobeNewsWire • 06/25/24
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual MeetingGlobeNewsWire • 06/10/24
Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' NowZacks Investment Research • 05/17/24
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineGlobeNewsWire • 05/09/24
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingGlobeNewsWire • 04/18/24
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsGlobeNewsWire • 04/10/24
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 04/04/24
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to BuyZacks Investment Research • 04/03/24
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsGlobeNewsWire • 03/28/24
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramGlobeNewsWire • 03/05/24
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersGlobeNewsWire • 02/20/24
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsGlobeNewsWire • 11/09/23
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingGlobeNewsWire • 11/01/23
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities ConferenceGlobeNewsWire • 10/10/23
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent DevelopmentsGlobeNewsWire • 08/10/23